Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217570 | 0.87 | MAPK1 (0.36) | RAB9AMAPK1ALDH1A1TP53MAPT | |
| SCHEMBL21218027 | 0.85 | ALDH1A1 (0.40) | TSHRSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL22085071 | 0.82 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL20079712 | 0.80 | TDP1 (0.47) | KDM4EALDH1A1TP53POLBMEN1 | |
| SCHEMBL20161778 | 0.79 | NAMPT (0.35) | MAPK1ALDH1A1TP53RXFP1 | |
| SCHEMBL19590948 | 0.79 | MTNR1A (0.46) | KDM4EALDH1A1POLB | |
| SCHEMBL19590941 | 0.76 | KMT2A (0.39) | SMN1; SMN2MAPK1KDM4EALDH1A1MEN1 | |
| SCHEMBL19590969 | 0.75 | LMNA (0.37) | RAB9ATSHRSMN1; SMN2MAPK1KDM4E | |
| SCHEMBL19590910 | 0.73 | ALDH1A1 (0.45) | TSHRSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL19590972 | 0.73 | MEN1 (0.47) | RAB9ATSHRSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | RAB9A 2599/4885TSHR 623/4885SMN1; SMN2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.